Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Abbott strikes deals with heart valve replacement companies

Abbott Laboratories (ABT.N) on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves. Abbott said it has agreed to acquire the equity in Minnesota-based Tendyne Holdings Inc […]

Read More »

Teva’s MS drug Copaxone has strong second-quarter sales

Teva Pharmaceutical Industries (TEVA.N), which this week revealed plans to buy Allergan’s (AGN.N) generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world’s biggest generic drug maker, said that global […]

Read More »

Sanofi’s diabetes sales slow, Genzyme’s jump

* Q2 Business net income up 4.2 percent, above expectations * Analyst says Toujeo sales “underwhelming” * CEO Brandicourt to unveil strategic plan on Nov.6, open to M&A * Shares down 0.45 percent (Adds details, shares, comments) By Matthias Blamont and Noëlle Mennella PARIS, July 30 (Reuters) – Sanofi reported lower second quarter sales for […]

Read More »

Four Boston Biotechs That Could Make M&A Moves This Year

July 29, 2015By Alex Keown, Breaking News Staff BOSTON – It’s been the year of deal making with more than $220 billion spent on mergers and acquisitions in the biotech industry, and it’s not over yet. Although no M&A activity has been announced, at least as of this writing, but given the atmosphere that […]

Read More »

PAREXEL International Stays Mum as 200 Ex-GlaxoSmithKline Workers are Reportedly Being Laid Off Today

July 30, 2015By Mark Terry, Breaking News Staff Reportedly, almost 200 former GlaxoSmithKline (GSK) employees who were transferred earlier this year to Parexel (PRXL) are being laid off today. The company has declined to comment directly on the matter. In December 2014, Boston, Mass.-based Parexel (PRXL) announced it was hiring 450 former GSK employees. […]

Read More »

Vertex Revenue Rises 20%

By Tess Stynes The Wall Street Journal Biography @TessStynes July 29, 2015 4:42 p.m. ET   Vertex Pharmaceuticals Inc. said its second-quarter revenue rose 20% on strong sales of Kalydeco that led the biotechnology company to raise its 2015 sales guidance for the cystic-fibrosis drug. Shares rose 1.5% to $127.50 in recent after-hours trading […]

Read More »

Teva Pharmaceuticals Stands To Lose Around $300 Million On Mylan Trade

Teva Pharmaceutical Industries may have found the deal it wanted in purchasing Allergan’s generics business for $40.5 billion in cash and stock, but the Israeli pharmaceutical company stands to lose around $300 million from its tactics in a now withdrawn unsolicited bid for competitor Mylan. Such are the costs of dealmaking in the red hot pharmaceutical and […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom